JAK2 V617F Mouse Spleen Pathology Analysis: Comprehensive Histopathological Evaluation for Myeloprol

JAK2 V617F mouse spleen pathology analysis delivers critical histopathological insights into myeloproliferative neoplasm (MPN) progression, extramedullary hematopoiesis, and myelofibrosis development. This comprehensive evaluation service integrates gross pathology, histological staining, immunohistochemistry, and semi-quantitative fibrosis grading to generate publication-ready data for preclinical studies and drug efficacy assessment.

Technical Overview

The JAK2 V617F gain-of-function mutation is the most common driver lesion in Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), present in approximately 95% of polycythemia vera (PV) patients and roughly 50–60% of essential thrombocythemia (ET) and primary myelofibrosis (PMF) cases. Constitutive activation of the JAK-STAT signaling pathway in JAK2 V617F knock-in mice faithfully recapitulates human MPN disease, producing polycythemia, leukocytosis, marked splenomegaly, and progressive myelofibrosis. The spleen is the primary disease-affected organ in this model, serving as the dominant site of extramedullary hematopoiesis (EMH) and a sensitive readout of disease burden and therapeutic response. Systematic spleen pathology analysis therefore constitutes an indispensable endpoint for evaluating disease progression, drug efficacy, and mechanism-of-action studies in JAK2 V617F mouse models.

Pathologically, the JAK2 V617F spleen exhibits progressive enlargement with disruption of normal architecture, including red pulp expansion due to trilineage EMH, megakaryocytic hyperplasia with abnormal clustering and emperipolesis, atypical megakaryocyte morphology, gradual white pulp atrophy, and—in advanced disease—increasing reticulin and collagen fibrosis. Quantitative and semi-quantitative assessment of these features provides reproducible, clinically translatable metrics for preclinical MPN research.

Testing Samples

Spleen Tissue from JAK2 V617F Knock-In Mice

Fresh spleen specimens harvested from JAK2 V617F knock-in mice (including conditional and hematopoietic-restriction models such as Vav1-Cre or Mx1-Cre driven lines) at user-defined disease stages, typically ranging from early polycythemia phase to advanced fibrotic phase. Matched wild-type and vehicle-treated controls are recommended for rigorous comparison.

Formalin-Fixed Paraffin-Embedded (FFPE) Blocks

Archived FFPE spleen blocks from completed in vivo studies are fully compatible with all routine staining, special staining, and immunohistochemistry workflows, enabling retrospective pathological evaluation of historical cohorts.

Frozen Tissue Sections

OCT-embedded frozen spleen sections are accepted for protocols requiring native antigen preservation, fluorescence-based detection, or downstream molecular assays on matched sections.

Sample Requirements

• Fresh spleen: harvested immediately post-euthanasia, weighed before fixation, and fixed in 10% neutral buffered formalin at a 10:1 fixative-to-tissue volume ratio for 18–24 hours.
• Spleen weight and body weight must be recorded to calculate the spleen index (spleen weight/body weight × 100%).
• Recommended orientation: longitudinal bisection to ensure representative sampling of both red and white pulp regions.
• FFPE blocks: standard 4–5 μm sections on positively charged slides.
• Sample transport: ambient shipment for FFPE material; dry ice shipment for frozen specimens.

Testing Items

Our JAK2 V617F mouse spleen pathology analysis platform covers the full spectrum of morphological and immunophenotypic endpoints required for comprehensive MPN characterization:

• Gross pathology: spleen weight, spleen-to-body weight ratio, and macroscopic morphology documentation.
• Histopathological evaluation (H&E): splenic architecture, red pulp expansion, white pulp atrophy, extramedullary hematopoiesis grading, megakaryocyte number, size, clustering, and nuclear atypia, and hemosiderin deposition.
• Myelofibrosis assessment: reticulin fiber staining (Gordon-Sweets or Gomori silver method) with semi-quantitative grading on a 0–4 scale adapted from WHO-adapted murine criteria; Masson's trichrome staining for collagen deposition in advanced fibrosis.
• Immunohistochemistry panel: CD41 or CD61 for megakaryocytes, Ter119 for erythroid precursors, Ly6G or MPO for granulocytic/myeloid cells, Mac-2 or F4/80 for macrophages, CD3 and B220/CD45R for T- and B-lymphoid compartments, and Ki-67 for proliferative index.
• Quantitative digital pathology: automated image analysis of positive area, cell density, and megakaryocyte cluster parameters using validated whole-slide imaging software.
• Integrated pathology reporting: board-certified veterinary pathologist review with full-color photomicrographs and publication-ready figure preparation.

Testing Methods

Tissue Fixation and Processing

Spleens are weighed, grossly examined, bisected longitudinally, and fixed in 10% neutral buffered formalin. Fixed tissues undergo automated dehydration, paraffin infiltration, and embedding, followed by sectioning at 4–5 μm. Standardized processing ensures reproducible morphology and antigen preservation across cohorts.

Routine and Special Staining

Hematoxylin and eosin staining is performed for comprehensive morphological assessment of splenic architecture, EMH, and megakaryocyte abnormalities. Reticulin silver staining selectively demonstrates type III collagen fiber networks, allowing semi-quantitative grading of myelofibrosis from grade 0 (no reticulin fibers) through grade 4 (diffuse, dense reticulin with collagen deposition). Masson's trichrome confirms collagen-type fibrosis in end-stage disease.

Immunohistochemistry

Sections undergo antigen retrieval, endogenous peroxidase blocking, and incubation with validated primary antibodies using polymer-based detection systems with DAB chromogen. Appropriate positive and negative controls are included in every run. Multiparameter panels are optimized specifically for murine splenic tissue to resolve lineage composition within expanded red pulp.

Quantitative and Semi-Quantitative Analysis

Lineage-positive areas and cell counts are quantified across standardized splenic regions using digital pathology platforms. Fibrosis grades are assigned by two independent observers using predefined criteria, with discrepancies resolved by consensus review. Statistical comparison between treatment groups, genotypes, and time points is provided upon request.

Applications

• Efficacy evaluation of JAK inhibitors (e.g., ruxolitinib, fedratinib) and next-generation selective JAK2 inhibitors using spleen index, EMH burden, and fibrosis grade as pharmacodynamic endpoints.
• Preclinical development of anti-fibrotic and disease-modifying therapies targeting myelofibrosis progression.
• Mechanistic studies of MPN pathogenesis, including inflammatory signaling, megakaryocyte–stromal interactions, and hematopoietic stem cell niche remodeling.
• Longitudinal natural history studies defining the transition from polycythemia phase to myelofibrotic phase in JAK2 V617F knock-in mice.
• Biomarker validation and companion diagnostic development for myeloid malignancy programs.
• Regulatory-enabling IND-enabling toxicology studies in genetically modified mouse models.

FAQ

Q: At what disease stage should spleens be collected from JAK2 V617F mice?

A: Collection timing depends on study objectives. Early polycythemia with splenomegaly is typically evident by 8–12 weeks in knock-in models, while overt reticulin fibrosis generally requires 4–6 months or longer. We recommend terminal collection at multiple time points to capture disease evolution, and our scientific team can advise on model-specific timelines.

Q: How is myelofibrosis graded in mouse spleens?

A: Reticulin staining is scored on a semi-quantitative 0–4 scale adapted from WHO human criteria and validated for murine spleen: grade 0 indicates no fibers; grades 1–2 reflect focal and expanding reticulin networks; grades 3–4 indicate diffuse dense fibrosis with early and established collagen deposition. Grading is performed by two independent pathologists blinded to treatment group.

Q: What control groups are recommended?

A: Age- and sex-matched wild-type littermates, heterozygous versus homozygous JAK2 V617F cohorts where applicable, and vehicle-treated disease controls are strongly recommended to support robust statistical interpretation.

Q: Can archived FFPE samples from completed studies be analyzed?

A: Yes. Retrospective analysis of FFPE spleen blocks is fully supported for H&E, special stains, and most immunohistochemical markers, provided tissue was properly fixed and processed.

Q: What is the typical turnaround time?

A: Standard H&E and special staining with pathology reports are delivered within 5–10 business days. Projects including immunohistochemistry panels, digital quantification, and integrated pathologist review typically require 2–3 weeks, depending on cohort size and panel complexity.

Q: Do you provide figure preparation for publication?

A: Yes. High-resolution photomicrographs, quantified scoring tables, and publication-ready composite figures aligned with journal requirements are available as part of our reporting package.